The Effect of the Inclusion of Soybean Flour on Glycemic Responses
- Disease/Condition
- Overweight and Obesity
- Drug/Device/Intervention
- Replacement of wheat flour by soyflour
- Study type
- Interventional
- Intervention type
- other
- Primary sponsor
- University of Illinois at Urbana-Champaign
- Location
- Champaign, United States of America
- Phase
- N/A
- Start date
- Mar 01, 2024
- End date
- Mar 25, 2025
- Enrollment
- 30 participants
Plasma glucose,Plasma insulin
Foods that release glucose rapidly, leading to spikes in blood sugar and insulin (known as
 high glycemic index foods), generate lower satiety responses than foods with low glycemic
 index. High glycemic index foods are also linked to an increased risk of developing diabetes.
 The partial replacement of carbohydrates in rich staple foods with soy flour has the
 potential to reduce glycemic response and improve satiety.
 
 In many regions of Latin America, as well as in the Middle East and North Africa (MENA)
 regions, bread is the staple source of calories, but it is a relatively poor source of
 balanced nutrition. Bread enriched with soy flour could provide higher dietary protein while
 moderating blood glucose (and insulin) spikes, which can help reduce insulin resistance and
 metabolic diseases. The results of this study could provide government and private human
 nutritionists with the evidence they need to formulate soy flour into bread, corn tortillas,
 and arepas for schools and homes.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06280625
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06280625 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Illinois at Urbana-Champaign and is currently Recruiting. The study focuses on Overweight and Obesity. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.